MRK Stock Recent News
MRK LATEST HEADLINES
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
RAHWAY, N.J.--(BUSINESS WIRE)--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives New Approvals in Japan for Certain Patients With NSCLC and Radically Unresectable Urothelial Carcinoma.
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.